Breaking News

Plasticell, GSK Ink iPSCs Screening Pact

Plasticell will use its CombiCult technology to screen combinations of molecules provided by GSK

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Plasticell, a biotechnology company specializing in stem cell screening and cell therapies, has entered into a collaboration with GlaxoSmithKline for the use of its stem cell screening technology, CombiCult, to optimize induced pluripotent stem cells (iPSCs) to specific blood cell lineages for GSK’s therapeutic research.   Plasticell will use its CombiCult technology to screen combinations of molecules provided by GSK to identify and optimize iPSC differentiation protocols. Plasticell’s techno...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters